Engineered T cells used in clinical study to treat nasopharyngeal carcinoma
2017
QIMR Berghofer Medical Research Institute, Brisbane, Australia(1)
The University of Hong Kong, Hong Kong, Hong Kong SAR of China(2)
The University of Hong Kong, Hong Kong, Hong Kong SAR of China(2)
The extension of adoptive T cell therapy to solid cancers remains a significant challenge. In this study, the researchers performed a clinical study to test a new type of engineered autologous T cell to specifically treat different degrees of nasopharyngeal carcinoma (NPC) patients. Cells were taken from the patients, modified ex vivo in GMP conditions and delivered back to the patients. Tolerability, safety and efficacy, including progression-free survival and overall survival, were evaluated. Overall, the clinical outcomes were promising and further suggest a potential role for this approach as a consolidation treatment following first-line chemotherapy.
Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response
Rajiv Khanna(1), Dora Kwong(2)
Added on: 07-29-2021
[1] https://www.tandfonline.com/doi/full/10.1080/2162402X.2016.1273311[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
